

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-39. (Canceled)

40. (Presently amended) A recombinant polypeptide comprising at least ten contiguous amino acids from the amino acid sequence of SEQ ID NO:3, which polypeptide:

- (i) is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3 and
- (ii) exhibits substantially no toxicity, or substantially reduced toxicity.

41-53. (Canceled)

54. (Presently amended) The recombinant polypeptide of claim 40, wherein said polypeptide comprises at least fifteen contiguous amino acids from the amino acid sequence of SEQ ID NO:3.

55-60. (Canceled)

61. (Presently amended) The recombinant polypeptide of claim 40 or 54, said polypeptide ~~comprising~~ having a molecular weight of at least 87 kDa.

62. (Presently amended) The recombinant polypeptide of claim 40 or 54, said polypeptide ~~comprising~~ having a molecular weight of at least 100 kDa.

63. (Presently amended) A recombinant polypeptide expressed from at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2, wherein said polypeptide:

- (i) is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3 and

(ii) exhibits substantially no toxicity, or substantially reduced toxicity.

64. (Presently amended) The recombinant polypeptide of claim 63, said polypeptide expressed from at least 30 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2.

65. (Presently amended) The recombinant polypeptide of claim 63, said polypeptide expressed from at least 45 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2.

66-71. (Canceled)

72. (Presently amended) The recombinant polypeptide of claim 63, 64, or 65, said polypeptide ~~comprising~~ having a molecular weight of at least 87 kDa.

73. (Presently amended) The recombinant polypeptide of claim 63, 64, or 65, said polypeptide ~~comprising~~ having a molecular weight of at least 100 kDa.

74. (Presently amended) An immunogenic, recombinant polypeptide comprising at least 10 contiguous amino acids of the amino acid sequence of SEQ ID NO:3, wherein said polypeptide exhibits substantially no toxicity or substantially reduced toxicity, and wherein said polypeptide is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3.

75. (Presently amended) The recombinant polypeptide of claim 74, said polypeptide comprising at least 15 contiguous amino acids of the amino acid sequence of SEQ ID NO:3.

76-81. (Canceled)

82. (Presently amended) The recombinant polypeptide of claim 74 or 75, said polypeptide ~~comprising~~ having a molecular weight of at least 87 kDa.

83. (Presently amended) The recombinant polypeptide of claim 74 or 75, said polypeptide ~~comprising~~ having a molecular weight of at least 100 kDa.

84. (Presently amended) An immunogenic, recombinant polypeptide comprising at least 5 contiguous amino acids expressed from at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2, wherein said polypeptide exhibits substantially no toxicity or substantially reduced toxicity and wherein said polypeptide is immunologically identifiable by antibodies that react specifically with the polypeptide expressed by the nucleotide sequence of SEQ ID NO:2.

85. (Presently amended) The recombinant polypeptide of claim 84, said polypeptide expressed from at least 30 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2.

86. (Presently amended) The recombinant polypeptide of claim 84, said polypeptide expressed from at least 45 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2.

87-92. (Canceled)

93. (Presently amended) The recombinant polypeptide of claim 84, 85, or 86, said polypeptide ~~comprising~~ having a molecular weight of at least 87 kDa.

94. (Presently amended) The recombinant polypeptide of claim 84, 85, or 86, said polypeptide ~~comprising~~ having a molecular weight of at least 100 kDa.

95-101. (Canceled)

DOCKET NO.: CHIR-0158
Application No.: 09/360,934
Office Action Dated: June 9, 2003

PATENT

Amendments to the Drawings

The attached sheet(s) of drawings includes changes to Fig(s) 1A, 1B, 1C, 2, 3, 4A, 4B, 4C, 4D, 4E, 4F, 5A, 5B, and 5C. The sheet(s), which includes Fig(s) 1A, 1B, 1C, 2, 3, 4A, 4B, 4C, 4D, 4E, 4F, 5A, 5B, and 5C, replaces the original sheet(s) including Fig(s) 1A, 1B, 1C, 2, 3, 4A, 4B, 4C, 4D, 4E, 4F, 5A, 5B, and 5C.

Attachment: Replacement Sheet(s)